Ocular Therapeutix Inc (OCUL)

Ocular Therapeutix, Inc. is a NASDAQ-listed biopharmaceutical company focused on therapies for retinal diseases and other eye disorders. The company uses its bioresorbable hydrogel-based formulation technology to develop and commercialize ophthalmic treatments in the United States. Its marketed product, DEXTENZA, is a dexamethasone ophthalmic insert used to treat post-surgical ocular inflammation and pain after eye surgery, as well as allergic conjunctivitis. In development, Ocular Therapeutix is advancing AXPAXLI, an axitinib intravitreal hydrogel currently in phase 3 trials for wet age-related macular degeneration and non-proliferative diabetic retinopathy, and OTX-TIC, a travoprost intracameral hydrogel that has completed phase 2 trials for open-angle glaucoma or ocular hypertension. The company also has a license and collaboration agreement with AffaMed Therapeutics Limited covering DEXTENZA and OTX-TIC. Founded in 2006, Ocular Therapeutix is headquartered in Bedford, Massachusetts.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.